Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
GlaxoSmithKline ( (GB:GSK) ) has issued an update.
GSK plc announced the vesting of Deferred Bonus Awards under its 2017 Deferred Annual Bonus Plan for its managers and directors. The awards, granted in 2022, have been exercised as nil-cost options or restricted awards over Ordinary Shares and American Depositary Shares (ADSs), with sales made primarily to cover tax liabilities. This move highlights GSK’s commitment to its remuneration policy and could impact shareholder value by aligning managerial interests with company performance.
More about GlaxoSmithKline
GlaxoSmithKline (GSK) plc is a leading pharmaceutical and healthcare company operating in the research, development, and manufacture of a range of healthcare products, including vaccines, medicines, and consumer healthcare products. The company is focused on improving the quality of life by enabling people to do more, feel better, and live longer.
YTD Price Performance: 6.76%
Average Trading Volume: 7,365,639
Technical Sentiment Consensus Rating: Sell
Current Market Cap: £58.9B
See more insights into GSK stock on TipRanks’ Stock Analysis page.
